

U

Outcomes: part II


B

Obtaining QoL values for QALYs


- Value judgement
- Search literature for published values
- Measure values
 - Direct valuation – by patients
 - Visual analogue
 - Standard Gamble
 - Time trade-off
 - Indirect valuation – by patients, public, others
 - Using standard tariffs for QoL instruments
 - Using direct valuation methods with scenarios

Visual analogue scale

- Many variants
- 'Thermometer' scale is the one mainly used.




Standard Gamble



Standard Gamble

- Probability p = QoL measure
- Advantages:
 - Based on axioms of utility theory
- Disadvantages:
 - Not many chronic diseases that approximate gamble
 - Subjects may find concept of probability difficult to understand

Time Trade-Off




Measuring outcomes: exercises 2 & 3


Challenges with QALYs: QoL measures

- **Validity** – does the instrument accurately measure what it is supposed to measure?
- **Reliability** – do you consistently obtain the same results using the instrument?
- **Sensitivity to change** – can the instrument measure (clinically important?) change?
- **Feasibility of use** – can the instrument be easily used with the population of interest?


The relationship between validity and reliability



Reliable but Not Valid



Valid but Not Reliable



Valid and Reliable

Validity of quality of life questionnaires


- No gold standard measure of health to compare EQ-5D to.
- Accumulate evidence over a range of aspects of validity:
 - *Content validity*: sufficient items and coverage?
 - *Construct validity*: anticipated relationships with other variables (e.g. disability, age, long standing illness are as anticipated)?
 - *Convergent validity*: correlates with other measures of same phenomenon?

Challenges with QALYs: QoL measures


- Validity – does the instrument accurately measure what it is supposed to measure?
- Reliability – do you consistently obtains the same results using the instrument?
- Sensitivity to change – can the instrument measure (clinically important?) change?
- Feasibility of use – can the instrument be easily used with the population of interest?

Potential trade-off between sensitivity and feasibility

Hydrodensitometry



Skin fold measure



UNIVERSITY OF
BIRMINGHAM

Sensitivity and feasibility of quality of life questionnaires

□ **Sensitivity:**

“The EQ-5D ...[is] more responsive than any of the other measures, except pain and doctor-assessed disease activity”

[Hurst et al. (1997) *Brit. J. of Rheum.*]

“The weighted TTO-score of EuroQoL-5D, ... did however not correspond with these [reduced psychotic symptoms] changes, which indicates that it is less sensitive to changes in social and psychological well-being.” [van de Willige et al. (2005) *Qual. Life Res*].

□ **Feasibility:**

- Patient burden (EQ-5D has 5 questions each with 3 possible responses).
- Valuation burden (EQ-5D has 243 possible health state permutations/ SF-6D has 18,000 possible permutations).

Challenges with QALYs: theory

- Assumes health status can be measured on a cardinal scale
- Assumes it is possible to equate x years in less than full health with y years in full health, where $y < x$
- Assumes can compare utility scores across individuals
- Possible to equate same state if one person deteriorating and the other improving (independence assumption)
- MU of health is constant, i.e. 2 QALYs to 1 person is equivalent to 1 QALY each to 2 people

Challenges with QALYs: methodology

- Possible to equate to death when death is unknown
- Different methods lead to different values
- Description of alternatives leads to different values
- Values creep towards 1 as health deteriorates with age
- Values differ depending upon the duration of the state
- Framing effects

Challenges with QALYs: ethical

- Life saving should always be a priority?
- Ageist?
- Attributes greater importance to maximising health than how that health is distributed
- Potential for discrimination?
- “Double jeopardy”?

Measuring outcomes: discussion

Selected reading

TEXTS

- **Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford University Press; 2005. Chapter 6.**
- **Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester, UK: John Wiley & Sons, Ltd; 2007. Chapter 10.**
- **Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2007.**

EARLY REFERENCES TO QALY METHODOLOGY

- **Williams A. Economics of coronary artery bypass grafting. British Medical Journal 1985; 291:326-329.**
- **Klarman H, Francis J, Rosenthal G. Cost-effectiveness analysis applied to the treatment of chronic renal disease. Medical Care 1966; 6(1):48-54.**
- **Torrance G. Measurement of health state utilities for economic appraisal. Journal of Health Economics 1986; 5:1-30.**

Selected reading II

OUTCOME MEASURES AND VALUATION OF HEALTH STATES

- Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *Journal of Health Economics* 2002; 21:271-292.
- Brooks R. EuroQol: the current state of play. *Health Policy* 1996; 37:53-72.
- Richardson J. Cost Utility Analysis: What Should Be Measured? *Social Science and Medicine* 1994; 39(1):7-21.
- Robinson A, Dolan P, Williams A. Valuing health status using VAS and TTO: what lies behind the numbers? *Social Science and Medicine* 1997; 45(8):1289-1297.
- Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. *Health Economics* 1996; 5(2):141-154.

VALIDITY AND ETHICS OF QALY METHODOLOGY

- Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. *Health Economics* 1999; 8:41-51.
- Loomes G, McKenzie L. The use of QALYs in health care decision making. *Social Science and Medicine* 1989; 28(4):299-308.
- Harris J. QALYfying the value of life. *Journal of Medical Ethics* 1987; 13:117-123.